Chemoimmunotherapy of experimental hepatic metastases

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Particulate glucan has shown efficacy in treating murine reticulum cell sarcoma (M5706) with liver metastasis.
• Soluble glucan represents a new therapeutic agent for investigation.

Purpose of the Study:

• To evaluate the therapeutic efficacy of a novel soluble glucan in combination with cyclophosphamide for treating hepatic metastatic disease.
• To assess the impact of this combination therapy on tumor burden, survival, and immune responses.

Main Methods:

• Male C57Bl/6J mice with subcutaneous M5706 sarcoma were treated with glucan, cyclophosphamide, or both, starting when hepatic metastases were evident.
• Therapeutic efficacy was assessed by measuring hepatic metastatic lesions, survival time, primary tumor weight, and in vitro immune cell activity.

Main Results:

• Combined glucan and cyclophosphamide therapy significantly reduced hepatic metastatic lesions and primary tumor weight.
• The combination therapy significantly extended median survival time and the time to 100% mortality in an additive manner.
• In vitro studies showed increased Kupffer cell tumoricidal activity, enhanced bone marrow proliferation, and splenocyte response to mitogens.

Conclusions:

• Soluble glucan combined with cyclophosphamide is an effective treatment for hepatic metastases in this murine sarcoma model.
• The combination therapy demonstrates immunomodulatory effects, enhancing anti-tumor immune responses.
• Glucan also exhibits a direct cytostatic effect on sarcoma cells in vitro.